Copyright
©The Author(s) 2019.
World J Gastroenterol. Jun 7, 2019; 25(21): 2539-2548
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2539
Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2539
Class of drugs | Response | Gene | Clinical utility |
5-Aminosalicylates1 | Nephrotoxicity | HLA-DRB1 | No (low incidence, high allele frequency) |
Thiopurines | Myelosuppression | TPMT NUDT15 | Yes |
Alopecia | NUDT15 | Yes | |
Pancreatitis | HLA-DQA1-HLA-DRB1 | Yes | |
TNF-antagonists | Immunogenicity | HLA-DQA1 | Yes |
- Citation: Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548
- URL: https://www.wjgnet.com/1007-9327/full/v25/i21/2539.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i21.2539